328 related articles for article (PubMed ID: 29293566)
21. Determining the HPV vaccine schedule for a HIV-infected population in sub Saharan Africa, a commentary.
Menon S; Rossi R; Kariisa M; Callens S
Virol J; 2018 Aug; 15(1):129. PubMed ID: 30115083
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South Africa.
Taku O; Businge CB; Mdaka ML; Phohlo K; Basera W; Garcia-Jardon M; Meiring TL; Gyllensten U; Williamson AL; Mbulawa ZZA
Int J Infect Dis; 2020 Jun; 95():176-182. PubMed ID: 32114194
[TBL] [Abstract][Full Text] [Related]
23. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain.
Purriños-Hermida MJ; Santiago-Pérez MI; Treviño M; Dopazo R; Cañizares A; Bonacho I; Trigo M; Fernández ME; Cid A; Gómez D; Ordóñez P; Coira A; Armada MJ; Porto M; Perez S; Malvar-Pintos A;
PLoS One; 2018; 13(8):e0201653. PubMed ID: 30075010
[TBL] [Abstract][Full Text] [Related]
24. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design.
Machalek D; Rees H; Chikandiwa A; Munthali R; Travill D; Mbulawa Z; Petoumenos K; Delany-Moretlwe S; Kaldor J;
BMJ Open; 2022 Feb; 12(2):e059968. PubMed ID: 35144959
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women.
Shikary T; Bernstein DI; Jin Y; Zimet GD; Rosenthal SL; Kahn JA
J Clin Virol; 2009 Oct; 46(2):107-11. PubMed ID: 19665924
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study.
Moodley JR; Constant D; Hoffman M; Salimo A; Allan B; Rybicki E; Hitzeroth I; Williamson AL
BMC Cancer; 2009 Aug; 9():275. PubMed ID: 19664216
[TBL] [Abstract][Full Text] [Related]
27. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
28. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
29. High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination.
Mbatha JN; Taylor M; Kleppa E; Lillebo K; Galappaththi-Arachchige HN; Singh D; Kjetland EF; Baay MFD; Mkhize-Kwitshana ZL
Infect Dis (Lond); 2017 Aug; 49(8):601-608. PubMed ID: 28403727
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy?
Panatto D; Amicizia D; Tanzi E; Bianchi S; Frati ER; Zotti CM; Lai PL; Bechini A; Rossi S; Gasparini R
BMC Infect Dis; 2013 Dec; 13():575. PubMed ID: 24313984
[TBL] [Abstract][Full Text] [Related]
31. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
32. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
33. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
34. Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial.
Sudenga SL; Torres BN; Botha MH; Zeier M; Abrahamsen ME; Glashoff RH; Engelbrecht S; Schim Van der Loeff MF; Van der Laan LE; Kipping S; Taylor D; Giuliano AR
J Infect; 2016 Jan; 72(1):60-9. PubMed ID: 26476151
[TBL] [Abstract][Full Text] [Related]
35. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
36. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
37. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of High-risk Nonavalent Vaccine-type Human Papillomavirus Infection Among Unvaccinated, Sexually Active Asian Female Adolescents With and Without Perinatally Acquired HIV Infection.
Sricharoenchai S; Kerr SJ; Gatechompol S; Hansudewechakul R; Dang HLD; Tran DNH; Teeratakulpisarn N; Chalermchockcharoenkit A; Achalapong J; Teeraananchai S; Singtoroj T; Phanuphak N; Sohn AH; Chokephaibulkit K;
Pediatr Infect Dis J; 2020 Jul; 39(7):615-619. PubMed ID: 32282527
[TBL] [Abstract][Full Text] [Related]
39. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
40. Importance of Lifetime Sexual History on the Prevalence of Genital Human Papillomavirus (HPV) Among Unvaccinated Adults in the National Health and Nutrition Examination Surveys: Implications for Adult HPV Vaccination.
Rositch AF; Patel EU; Petersen MR; Quinn TC; Gravitt PE; Tobian AAR
Clin Infect Dis; 2021 May; 72(9):e272-e279. PubMed ID: 32710745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
